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Background: Dopamine receptors are involved in midbrain reward circuit activation. Polymorphisms in two
dopamine receptor genes, DRD2 and DRD4, have been associated with altered perception of food reward and
weight gain. The objective of this study was to determine whether the same risk alleles were associated with
overweight/obesity and with lower reduction of overweight after a 1-year lifestyle intervention.
Methods: In a longitudinal study the association of polymorphisms in DRD2 (rs18000497, risk allele: T, formerly A1
allele at the TaqI A1 polymorphism) and DRD4 (variable number of tandem repeats (VNTR); 48 bp repeat in exon III;
risk alleles: 7 repeats or longer: 7R+) was tested on weight loss success following a 1-year lifestyle childhood obesity
intervention (OBELDICKS). An additional exploratory cross-sectional case-control study was performed to compare
the same DRD polymorphisms in these overweight/obese children and adolescents versus lean adult controls.
Subjects were 423 obese and 28 overweight children participating in lifestyle intervention (203 males), age median
12.0 (interquartile range 10.0–13.7) years, body mass index - standard deviation score (BMI-SDS) 2.4 ± 0.5; 583 lean
adults (232 males); age median 25.3 (interquartile range 22.5–26.8) years, BMI 19.1 ± 1.9 kg/m2. BMI, BMI-SDS and
skinfold thickness measures were assessed at baseline and after 1 year; genotyping was performed for DRD2 risk
variant rs1800497 and DRD4 exon III VNTR.
Results: The DRD2 genotype had a nominal effect on success in the weight loss intervention. The weakest BMI-SDS
reduction was in children homozygous for two rs1800497 T-alleles (n = 11) compared to the combined group with
zero (n = 308) or one (n = 132) rs1800497 T-allele (-0.08 ± 0.36 vs. -0.28 ± 0.34; p < 0.05). There was no association
between the DRD4 VNTR alleles and genotypes and success in the weight loss intervention. No associations of the
risk alleles of the DRD2 and DRD4 polymorphisms and obesity were observed in the cross-sectional part of the study.
Conclusions: We did not find association between polymorphisms in DRD2 and DRD4 genes and weight status.
However, obese carriers of two DRD2 rs1800497 T-alleles may be at risk for weak responses to lifestyle interventions
aimed at weight reduction.
Trial registration: Obesity intervention program “Obeldicks” is registered at clinicaltrials.gov (NCT00435734).
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Genetic factors are involved in individual body weight
variation. Midbrain dopamine circuits may play an im-
portant role in both addiction and normal eating behavior
as they are involved in reward processing, particularly
dopaminergic signaling via dopamine receptors 2 and 4
(DRD2, DRD4) [1-3].
Dopamine signaling plays a critical role in the striatum,
a brain area that is critically involved in reward and central
satiety signaling [4]. In addition, the nucleus accumbens
(NAc) and its dopaminergic input from the ventroteg-
mental area (VTA) have been implicated in reward-
seeking behavior, including enabling motor movement
towards a reward [5]. These areas are part of a hunger
mediating network that includes areas such as the
insula, VTA, NAc and anterior cingulate cortex (ACC),
which are more active during hunger and fasting and
motivate consumption of calorically-dense foods [4,6-8].
Overweight individuals show increased attention to
palatable food and find it more rewarding [9]. It is has
been suggested that obese individuals tend to overeat in
order to compensate for a weak activation of the meso-
limbic reward system in response to food intake [10,11].
This could be a consequence of high fat and high carbo-
hydrate intake. However, it is also possible that altered
dopamine signaling is a risk factor for development of
obesity and thus being a cause rather than a consequence
of obesity. The concept of altered reward sensitivity has
also been discussed in the context of binge eating disor-
ders, substance addiction, and impulsivity [1]. Obese
individuals may show hypofunctioning of food reward
circuitry while resting, but hyperfunctioning when ex-
posed to food or food cues [12,13]. However, the role
of dopamine, a primary component of reward pathways,
in obesity is still controversial [14-16].
Evidence suggests that dopamine-related genes moder-
ate reward circuitry in anticipation or response to food in-
take. The most commonly tested and referred to DRD2
polymorphism is rs1800497 (the risk allele T is also known
as the TaqI A1 allele), which was later shown to lie within
the adjacent ankyrin repeat and kinase domain containing
1 gene (ANKK1) [17]. In humans a low DRD2 density is
associated with the rs1800497 T-allele [18], putatively
making individuals less sensitive to the activation of
dopamine-based reward circuitry and rendering them
more likely to overeat. In fact, binge eating has been
shown to be more frequent among obese adults who were
homo- or heterozygous for the T allele at rs1800497 [19].
Additional evidence implicates DRD4 signaling in re-
ward sensitivity. DRD4 is a postsynaptic receptor that is
principally inhibitory of the second messenger adenylate
cyclase. DRD4s are predominantly localized in areas that
are innervated by mesocortical projections from the
ventral tegmental area, including the prefrontal cortex,cingulate gyrus, and insula [20]. The DRD4 exon III
variable number tandem repeat “7 repeats or longer”
allele (DRD4 7R+) has been linked to deficient dopa-
mine functioning [20,21].
In functional neuroimaging studies Stice et al. showed
that blunted post-meal dorsal striatal activation in carriers
of at least one DRD2 rs1800497 T or DRD4 7R + allele(s)
was associated with stronger body mass index (BMI) in-
crease in future [9,22]. Therefore we focused on these
two variants in children. The question is whether gene
variants of dopamine receptors moderate treatment re-
sponses and predict success in an obesity intervention
based on behavioral modification. There are no studies
in children investigating the effect of dopamine receptor
risk alleles on outcomes of obesity intervention.
In this study, we genotyped DRD2 rs1800497 and DRD4
variable number of tandem repeats (VNTR) in overweight
and obese children who underwent a lifestyle interven-
tion, as well as in a lean adult control group. We hypothe-
sized, that the presence of DRD2 rs1800497 T and/or
DRD4 7R + alleles are more frequent among overweight/
obese vs. lean subjects and are associated with weaker




Study group 1 (cases) comprised 28 overweight and 423
obese children (see Table 1; 203 males, age median 12.0 y,
interquartile range 10.0 – 13.7 y, for all 451 studied
children), who participated in a structured lifestyle inter-
vention program (Obeldicks). These children were exam-
ined at the outpatient obesity referral centers in Datteln,
Germany. Children with syndromal obesity, diabetes
mellitus or other endocrine or psychiatric disorders were
excluded from the study. Study group 2 (controls) com-
prised 583 German normal and underweight healthy
young adult controls (see Table 1; 231 males; age median
25.3, interquartile range 22.5 – 26.8 y, for details see [23]).
Their median BMI was 18.6 (interquartile range 17.7 –
20.6) kg/m2. The study was approved by the institutional
ethics committees of the Universities Witten/Herdecke
and Duisburg-Essen. Written informed consent was
obtained from all children and, in case of minors, their
parents in accordance with institutional guidelines and
with the Declaration of Helsinki.
Anthropometric data and obesity related measures
Body weight of patients and controls was evaluated using
the following BMI calculation: BMI = weight [kg]/ height2
[m2]. In children this was expressed as a standard deviation
score (BMI-SDS) (see statistical methods). Overweight and
obesity were defined according to the International Task
Force of Obesity by BMI-SDS between the 90th and 97th
Table 1 Association of DRD2/ANKK1 rs1800497 genotypes to baseline parameters and outcomes of a weight loss
intervention among overweight/obese children (N = 451)
CC (A2/A2) CT (A1/A2) TT (A1/ A1) CC&CT Additivea Recessive (T) Dominant (T)
N 308 132 11 440
Baseline BMIb 27.45 ± 4.49 27.19 ± 4.42 26.49 ± 2.45 27.38 ± 4.46 0.686 0.197 0.561
Change in BMIb,e -0.41 ± 1.95 -0.99 ± 1.93 0.75 ± 2.51 -0.58 ± 1.96 0.002 0.023 0.024
Baseline BMI-SDSc 2.37 ± 0.50 2.35 ± 0.48 2.13 ± 0.38 2.36 ± 0.50 0.285 0.125 0.460
Change in BMI-SDSc,e -0.26 ± 0.34 -0.34 ± 0.33 -0.08 ± 0.36 -0.28 ± 0.34 0.015 0.060 0.090
Baseline triceps skinfold (mm)b,d 31.29 ± 8.80 31.28 ± 11.22 32.05 ± 6.25 31.29 ± 9.55 0.966 0.932 0.850
Change in triceps skinfold (mm)b,d -2.40 ± 10.41 -5.38 ± 11.59 -1.86 ± 6.47 -3.27 ± 10.83 0.053 0.639 0.027
Baseline subscapular skinfold (mm)b,d 30.12 ± 9.75 29.53 ± 11.38 30.82 ± 5.95 29.95 ± 10.25 0.837 0.873 0.741
Change in subscapular skinfold (mm)b,d -2.71 ± 11.05 -3.24 ± 10.67 2.91 ± 7.67 -2.87 ± 10.92 0.204 0.086 0.952
All values are mean ± SD. After adjustment for multiple comparisons P-values <0.025 were considered as significant (in bold letters). aAdditive (overall) p-value for
the model comparing CC, CT, TT.
bLinear Regression P-value adjusted for age, puberty and gender. cUnadjusted linear regression P-value. dMissing values 1-4%; eMissing values 5-22%.
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according to age and gender using population specific
data. Height was measured to the nearest centimeter
using a rigid stadiometer. Weight was measured in under-
wear to the nearest 0.1 kg using a calibrated balance scale.
Height-SDS, weight-SDS and BMI-SDS were calculated
according to German percentiles as mentioned in a previ-
ous study [24]. Pubertal developmental stage was assessed
using the standards from Marshall and Tanner. Triceps
and subscapularis skinfold thicknesses were measured in
duplicate using a caliper and averaged [25].
Obesity intervention
As part of the study, all 451 children who were treated
at the Vestische Kinderklinik, Datteln, participated in the
1-year German obesity intervention program “Obeldicks”
which has been described previously in more detail [26]
and is registered at clinicaltrials.gov (NCT00435734). Briefly,
the 1-year intervention program is based on physical exer-
cise, nutrition education, and behavioral therapy, including
the individual psychological care of the child and his or her
family [26]. The exercise therapy took place once per week
throughout the whole intervention year.
Dopamine receptor gene variants
Blood samples were provided from all participants to
extract DNA using a standard salting-out method. We
genotyped the DRD2 single nucleotide polymorphism
(SNP) rs1800947 as described previously [9,22]. Geno-
typing was performed by PCR (298 bp amplicon using the
primers: forward 5′-GGCTGGCCAAGTTGTCTAAA,
reverse 5′-CCTGAGTGTCATCAACCTCCT) and sub-
sequent digest by TaqI; detailed conditions for the PCR-
RFLP can be obtained by the authors. The DRD4 exon
III VNTR was genotyped as we described previously[27]. Genotypes of 82 of the underweight controls had
been used for our previously published association
study [27].
Statistical analysis
Means and standard deviations were calculated for all
measures, stratified by genotype. The first analysis sep-
arately examined the relationship of DRD2 rs1800497
and DRD4 VNTR to BMI in all adult and child subjects.
DRD2 rs1800497 genotypes were CC, CT or TT. A com-
bined group (CC and CT) was compared to subjects
who were homozygous for the rs1800497 T (risk) allele.
DRD4 exon III VNTR polymorphism was classified as
having no 7R+, one 7R + or two 7R + alleles . The second
analysis tested obesity intervention outcomes in obese
children in relation to DRD2 and DRD4 genotypes. Longi-
tudinal changes in BMI-SDS over the course of the 1 year
“Obeldicks” program were evaluated. The rationale for
testing an additive genetic model was to test the effect
of zero vs. one vs. two minor alleles on BMI status and
obesity intervention outcomes, which is usually the best
choice if the true genetic model is not known [28]. In
addition, we tested the dominant model under the as-
sumption that one risk allele is sufficient for development
of obesity and to affect obesity intervention outcomes
[9,22]. As the genetic model is not well established for
the studied variants, we finally also investigated whether
two risk alleles are necessary to have an impact on BMI
status and intervention outcomes in a recessive model
(homozygous for the risk allele versus all other geno-
types). Due to the varying distribution of BMI over dif-
ferent stages of childhood, the LMS method was utilized
to calculate BMI-SDS as a normalized measurement for
the degree of overweight. The LMS method was chosen
















Figure 1 Change of BMI-SDS after 1 year lifestyle intervention
in 451 overweight/obese children. *p = 0.046 homozygous TT risk
allele status vs. CC and CT combined by students t-test.
Table 2 Delta BMI z-score changes in quartiles vs.
rs1800497T allele status, n = 440 obese children participating
in lifestyle intervention
Quartile: 1 2 3 4
Delta BMI z-score -0.72 ± 0.24 -0.36 ± 0.06 -0.15 ± 0.07 0.12 ± 0.13
CC N(%) 70(23.2) 73(24.2) 82(27.2) 77(25.5)
CT N(%) 39(30.7) 35(27.6) 26(20.5) 27(21.3)
TT N(%) 1(9.1) 2(18.2) 2(18.2) 6(54.5)
Fisher’s exact test p = 0.154.
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German population-specific data [24,29]. The M and S
curves correspond to the median and coefficients of vari-
ation (CVs) of BMI for German children at each age and
gender, whereas the L curve allows for the substantial
age-dependent skewness in the distribution of BMI. The
assumption underlying the LMS method is that after
Box-Cox power transformation, the data at each age are
normally distributed [29]. We investigated the effect of
the genotypes on anthropomorphic measurements both
at baseline and the changes during weight intervention.
Linear regression analyses were performed using Stata
12 software (Stata Corp, College Station, TX) and were
calculated both unadjusted and adjusted for gender, age,
puberty status and BMI-SDS as applicable. No. of risk
alleles, gender, and puberty status were treated as nom-
inal variables for all analyses. Overall effects were tested
and indicator variables were used to assess the associa-
tions between risk and non-risk genotypes.
Student’s t-tests were performed using Prism 5 software
(GraphPad, La Jolla, CA) for two group comparisons of
measurements between combined zero or one rs1800497
T vs. non-rs1800497 T alleles. All reported p-values in
tables are two-sided, nominal, and are adjusted by
Bonferroni correction [28] for multiple testing (2 tests:
BMI status, skinfold thickness) and to confounders if
stated. The consistency of genotype frequencies was tested
with Hardy Weinberg equilibrium. Pearson’s chi squared
tests were performed using Stata 12 software (Stata Corp,
College Station, TX) for comparison of DRD2 rs1800497
T allele and DRD4 7R + allele and genotype distributions
between children and lean adult controls.
Results
In longitudinal data analyses of treatment outcomes,
there was an overall effect of DRD2 genotype on weight
loss success (Table 1). The strongest BMI and BMI-SDS
reductions occurred among children with the DRD2 CT
genotype. The intervention had a weak or no effect among
children with TT genotypes as compared to children with
no or one rs1800497 T allele (CC, CT) (Table 1, Figure 1).
Of the 11 probands homozygous for the T allele at
rs1800497, 6 were in the quartile of the weakest BMI
z-score reduction (Fisher’s exact test across quartiles
p = 0.154, Table 2). There was a trend in changes of
subscapular skinfold thickness showing no reduction
in TT vs. reduction in CC and CT (Table 1).
We detected no association of DRD4 VNTR alleles or
genotypes on BMI, BMI-SDS or skinfold thickness at
baseline. Nor were differences present in longitudinal
changes in these parameters among the DRD4 7R + allele
groups (Table 3).
In the additional case control study, risk allele distri-
bution was compared between obese children and leancontrols and there was no difference in the proportion
of subjects with one (CT), two (TT), or no (CC) T alleles
at rs1800497 (p-value = 0.840, χ2 = 0.348; Pearson’s Chi-
squared test, see values in Table 1). Similarly, the distri-
bution of zero, one, or two risk alleles of DRD4 7R +
was not different between the obese children vs. lean
controls (p-value = 0.728; χ2 = 0.636; Pearson’s Chi-squared
test) (Table 4).
Discussion
The current study examined associations between a DRD2
and a DRD4 polymorphism and weight loss during a life-
style intervention. There was an overall effect of DRD2
genotype on BMI reduction in the lifestyle intervention.
Homozygotes for the rs1800497 T allele showed a lower
weight status reduction in response to lifestyle interven-
tion than carriers of the other genotypes. There was no
association of the DRD4 VNTR polymorphism with the
analyzed phenotypes. This is the first report on the associ-
ation of dopamine receptor variant status and childhood
obesity intervention outcomes. However, in the additional
cross-sectional part of the study, we did not find associ-
ation for either the DRD2 or the DRD4 polymorphism
alleles or genotypes and overweight or obesity.
We postulated that both DRD gene polymorphisms
evoke excessive calorie consumption, which may reflect
Table 3 Association of DRD4 exon III variable number of tandems repeat genotypes to baseline parameters and
outcomes of a weight loss intervention in 451 overweight/obese children
No 7R + alleles One 7R + allele Two 7R + alleles Additivea Recessive Dominant
N 285 148 18
Baseline BMIb 27.25 ± 4.39 27.41 ± 4.58 28.97 ± 3.81 0.279 0.355 0.456
Change in BMIb,d -0.48 ± 1.95 -0.62 ± 2.00 -1.01 ± 2.42 0.479 0.434 0.362
Baseline BMI SDSc 2.34 ± 0.48 2.38 ± 0.53 2.5 ± 0.3 0.413 0.336 0.253
Change in BMI SDSc,d -0.25 ± 0.32 -0.32 ± 0.36 -0.30 ± 0.43 0.358 0.746 0.152
Baseline triceps skinfold (mm)b,e 31.17 ± 9.45 30.63 ± 7.08 34.82 ± 5.11 0.167 0.107 0.825
Change in triceps skinfold (mm)b,e -2.94 ± 11.29 -3.03 ± 6.45 -4.03 ± 6.71 0.915 0.867 0.976
Baseline subscapular skinfold (mm)b,e 29.95 ± 10.58 29.31 ± 8.29 32.45 ± 5.56 0.440 0.344 0.776
Change in subscapular skinfold (mm)b,e -2.73 ± 11.09 -2.04 ± 9.15 -3.27 ± 9.74 0.805 0.935 0.573
All values are mean ± SD. aAdditive (overall) p-value for the model comparing 0, 1, or >1 repeats.
bLinear Regression P-value adjusted for age, puberty and gender. cUnadjusted linear regression P-value. dMissing values 1-4%; eMissing values 5-20%.
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leading to obesity and poor obesity intervention out-
comes [30]. Response inhibition refers to the neural
process by which unnecessary or inappropriate motor
action is suppressed [31-35]. Impaired response inhib-
ition is a behavioral trait of which impaired satiety may
be one manifestation. A related trait – impulsivity – has
been linked to obesity [36-38] and poor obesity treat-
ment outcomes in children [37].
In the longitudinal part of the study, gene polymor-
phisms in DRD2 did predict (nominal p-value < 0.05)
outcomes in the lifestyle intervention. Carriers of two
DRD2 rs1800497 T alleles may be at risk for weaker
weight status reduction in response to lifestyle interven-
tion. This group seems to be enriched in lowest quartile
for BMI z-score reduction (Table 2). However, these re-
sults need to be regarded with caution as they did not
reach statistical significance upon Bonferroni correction.
Thus, even though the number of children in this group
was a small proportion of the total children enrolled,
children with the TT genotype may represent a larger
proportion of children who do not do well in lifestyleTable 4 Distribution of DRD2/ANKK1 rs1800497 alleles and DR
relation to BMI among all adult and pediatric subjects
Adults (lean)
N (% of total) n = 583 Age Sex BMI
rs1800497
CC (A2/A2) 407 (69.8) 25.4 ± 4.5 161 M/246 F 19.2 ± 2.0
CT (A1/A2) 161 (27.6) 25.1 ± 4.3 64 M/97 F 19.1 ± 1.9
TT (A1/A1) 15 (2.6) 24.4 ± 3.0 6 M/9 F 18.2 ± 1.1
DRD4 7R+
No 357 (61.2) 25.6 ± 4.6 149 M/208 F 19.2 ± 2.0
One 198 (34.0) 24.8 ± 4.1 71 M/127 F 19.0 ± 1.9
Two 28 (4.8) 25.4 ± 4.0 11 M/17 F 18.8 ± 1.5
Age and BMI values are Mean ± SD.interventions. We did not find evidence that carriers of
one rs1800497 T allele are at risk for obesity or re-
duced success during obesity intervention which needs
to be discussed in context with prior results of func-
tional neuroimaging studies by Stice et al. in which the
presence of one risk allele was sufficient to modulate
the relation between food reward and future weight gain
[9,22]. Although the authors reported that the rs1800497
T (A1) allele status did not predict increase in BMI over
follow-up, they found that the rs1800497 T allele moder-
ated the relations of brain responses during exposure to
appetizing vs. unappetizing food to risk for increases in
BMI over the 1-year follow-up. Therefore, it is possible
that the effects of DRD variant status on neuronal activa-
tion is stronger than on weight status per se, as individuals
in our study were seeking weight loss and therefore may
already have compensated somewhat for this predispos-
ition. Moreover, our data support the hypothesis that chil-
dren with a single risk allele may actually be particularly
responsive to lifestyle intervention as they demonstrated
significantly greater reductions in BMI. Behavioral therapy
and nutrition education might be sufficient to engageD4 exon III variable number of tandems repeat alleles in
Children (overweight or obese)
N (% of total) n = 451 Age Sex BMI BMI-SDS
308 (68.3) 10.8 ± 2.6 139 M/169 F 27.5 ± 4.5 2.4 ± 0.5
132 (29.3) 10.7 ± 2.7 60 M/72 F 27.2 ± 4.4 2.3 ± 0.5
11 (2.4) 11.3 ± 1.7 4 M/7 F 26.5 ± 2.5 2.1 ± 0.4
285 (63.2) 10.8 ± 2.6 135 M/150 F 27.2 ± 4.4 2.3 ± 0.5
148 (32.8) 10.8 ± 2.7 62 M/86 F 27.4 ± 4.6 2.4 ± 0.5
18 (4.0) 11.4 ± 2.1 6 M/12 F 29.0 ± 3.8 2.5 ± 0.3
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population, which, if our findings are replicated, would be
encouraging.
Humans who are homo- or heterozygous for DRD4
7R + alleles have shown higher peak body mass in cohorts
at risk for obesity [39,40], greater food cravings [41], as
well as smoking, alcohol, and drug cravings [42-44]. We
did not find association for DRD4 7R + allele carriers to
obesity, or weight loss success in a childhood obesity life-
style intervention. In addition, there are also no published
studies showing an association between DRD4 7R + alleles
and weight status or responses to obesity intervention in
this age group. Potentially this is not a predominating fac-
tor for weight status and response to obesity intervention
in the age group of our studied children.
Studying children is advantageous as the obesity is not
yet chronic and exposure to a calorie dense diet was not
very long. Longer exposure has been hypothesized to re-
duce dopamine signaling via receptor down-regulation.
In the additional cross-sectional part of the study, we
did not find evidence that the risk alleles at the tested
DRD2 and DRD4 polymorphisms are associated with
measures of obesity. These data are not inconsistent with
prior findings, as the DRD2 rs1800497 T allele was
associated with increased body mass in some studies
[45-47], while other studies do not show association
[48,49]. In recent a longitudinal study investigating the
association between change in BMI from adolescence to
young adulthood and polymorphisms in genes involved
in serotonergic and dopaminergic functioning, no sig-
nificant associations were found between DRD2 rs1800497
T allele or DRD4 7R + allele and BMI categories [50].
However, a polymorphism in the monoamine oxidase A
(MAOA) gene, that encodes an enzyme that metabo-
lizes dopamine, serotonin and noradrenaline, was asso-
ciated with increased BMI which further supports that
the gene variants involved in dopamine metabolism
might have an impact on body weight change.
Strengths of this study include the relatively large
sample size for the childhood obesity intervention and
the longitudinal study design. However, limitations persist
that should be discussed. First, adiposity was assessed by
indirect estimations (BMI, BMI-SDS; skinfold thickness)
[51]. Second, we analyzed the effects of the DRD gene
polymorphisms only on anthropometric measures and
were not able to include any behavioral tests or data on
eating. Future studies should include assessment of eating
behaviors. Third, in the exploratory cross-sectional part
of our study, the lean control group consisted of young
adults. Although obese children and adolescents fre-
quently become obese adults [52] and lean adults were
most likely lean children, it is possible that some of the
lean adult controls were obese during childhood. However,
we deem lean adults as better controls for associationstudies than lean children, as a proportion of the lean
children might become obese adults. Hence, lean chil-
dren might harbor ‘obesity alleles’ and therefore decrease
the power of the association study. Finally, we investigated
the effect of two DRD polymorphisms in our study, but
other DRD polymorphisms could have an impact as
well [3,50,53].
Conclusions
Our findings contribute to a further understanding of the
relation between alterations in dopamine receptor struc-
ture and/or function that have previously been shown to
lead to compromised dopamine signaling in reward brain
areas and higher risk for developing obesity. Although we
did not demonstrate an association between DRD4 VNTR
and weight status, we found that carriers of DRD2 rs1800497
T alleles are at risk for weak responses to lifestyle inter-
ventions aimed at weight reduction.
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